930 WINTER STREET, WALTHAM, MA
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
License Agreement with Paragon Therapeutics - Jade Biosciences, Inc.
Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Amendment to Articles of Incorporation Approved at 2026 Annual Meeting
Announces Pricing of Public Offering of Common Stock
Reg. FD, Other Events
Annual Report to Security Holders
Andrew King Appointed President, Research & Development at Jade Biosciences
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership